Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding

Mari Jibu; Yoshiyuki Osabe

doi:doi:10.11648/j.ajist.20180203.11

| Peer-Reviewed

Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding

Mari Jibu, Yoshiyuki Osabe

Published in American Journal of Information Science and Technology (Volume 2, Issue 3)

Received: 10 September 2018 Accepted: 6 October 2018 Published: 27 October 2018

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

For the sake of providing evidences that contribute to policy making or strategy planning in AMED (a Japanese version of the NIH) and pharmaceutical companies, this study tried to analyze a current state of the pharmaceutical industry based on new indicators and forecast the future thorough a series of papers. In this article, this study tried to give an overview of the funding trends for the drug development o this study analyzed 18,845 contracts between licensors and partners whose headquarters are located in the U.S. As a result, Major companies, SMEs are dealing not only with other SMEs but also dealing actively with government agencies and foundations in U.S. Government involvement is one of the most important aspects, because it provides innovation system structure to link each entity. The foundation also plays the important role as a funding partner in U.S. Focusing the role of SMEs in U.S., there are some transactions that SMEs buy the candidates of major companies on the discovery phase. On the other hands, investment from venture capital firms in Japan is one tenth of that in US. In AMED, introductory service of venture capital, commercialization, and government procurement will become useful systems.

Published in	American Journal of Information Science and Technology (Volume 2, Issue 3)
DOI	10.11648/j.ajist.20180203.11
Page(s)	64-73
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2018. Published by Science Publishing Group

Keywords

AMED, NIH, Pharmaceuticals, R&D, EBPM, Funding, SBIR, Venture Capital

References

[1]	Lukach, Ruslan and Joseph Plasmans. 2002. “Measuring knowledge spillovers using patent citations: evidence from the Belgian firm’s data” CESifo Working Paper NO.754 Category 9: Industrial organization.
[2]	Squicciarni, Mariagrazia, Helene Dernis and Chiara Criscuolo. 2013. “Measuring Patent Quality: Indicators of Technological and Economic Value” OECD/DSTI/DOC 3
[3]	OECD. 2013. OECD Science, Technology and Industry Scoreboard 2013: Innovation for Growth. Paris, France: OECD Publishing
[4]	Booth, Bruce, and Rodney Zemmel. 2004. “Prospects for Productivity.” Nature Reviews Drug Discovery 3, 451-456
[5]	Yoshiyuki OSABE, Mari JIBU. Development of new indicators for the launch of a Japanese version of the NIH (1): An overview and future prospects of pharmaceutical industry based on new indicators. Journal of Information Processing and Management. 2013, Vol. 56, No. 7, p. 448. https://www.jstage.jst.go.jp/article/johokanri/56/7/56_448/_article/-char/en
[6]	Yoshiyuki OSABE, Mari JIBU. Development of new indicators for the launch of a Japanese version of the NIH (2): A technology-specific overview and future prospects of pharmaceutical industry. Journal of Information Processing and Management. 2013, Vol. 56, No. 9, p. 611. https://www.jstage.jst.go.jp/article/johokanri/56/9/56_611/_article/-char/en
[7]	Yoshiyuki OSABE, Mari JIBU. Development of new indicators for the launch of a Japanese version of the NIH (3): Analysis of entities conducting pharmaceutical R&D activities. Journal of Information Processing and Management. 2014, Vol. 56, No. 10, p. 685. https://www.jstage.jst.go.jp/article/johokanri/56/10/56_685/_article/-char/en
[8]	Mari JIBU, Yoshiyuki OSABE. Development of new indicators for the launch of a Japanese version of the NIH (4): Refined indicators for patents linked with marketed drugs and pipelines. Journal of Information Processing and Management. 2014, Vol. 57, No. 1, p. 29. https://www.jstage.jst.go.jp/article/johokanri/57/1/57_29/_article/-char/en
[9]	Mari JIBU, Yoshiyuki OSABE. Development of new indicators for the launch of a Japanese version of the NIH (5): Analysis based on refined indicators for patents linked with marketed drugs and pipelines. Journal of Information Processing and Management. 2014, Vol.57, No.3, p.178. https://www.jstage.jst.go.jp/article/johokanri/57/3/57_178/_article/-char/en
[10]	Yoshiyuki OSABE, Mari JIBU. Development of new indicators for the launch of AMED (6): A disease-specific overview and future prospects of pharmaceutical industry. Journal of Information Processing and Management. 2014, Vol. 57, No. 5, p. 323. https://www.jstage.jst.go.jp/article/johokanri/57/5/57_323/_article/-char/en
[11]	Mari JIBU, Yoshiyuki OSABE. Development of new indicators for the launch of AMED (8): Knowledge flows of the pharmaceutical innovation system. Journal of Information Processing and Management. 2014, Vol.57, No.8, p.562. https://www.jstage.jst.go.jp/article/johokanri/57/8/57_562/_article/-char/en
[12]	Odagiri Hiroyuki. "Corporate Boundaries" in Pharmaceutical Research and Development, Pharmaceutical Industry Organization Theory, The University of Tokyo Press, 2002, p. 117-151.
[13]	Foundation Center. http://www.foundationcenter.org/findfunders/topfunders/top100giving.html, (accessed 2018-09-06).
[14]	Ministry of Finance. Points of budget for science and technology in FY2014, 2013, http://www.mof.go.jp/budget/budger_workflow/budget/fy2014/seifuan26/05-07.pdf, (accessed 2018-09-06).
[15]	SBIB/STTR. http://sbir.gov/, (accessed 2018-09-06).
[16]	OECD Science, Technology and Industry Scoreboard 2013. http://www.oecd-ilibrary.org/science-and-technology/oecd-science-technology-and-industry-scoreboard-2013_sti_scoreboard-2013-en, (accessed 2018-09-06).
[17]	Venture Enterprise Center. Survey result of venture capital investment trend in FY 2013 (preliminary report). http://www.vec.or.jp/wordpress/wp-content/files/2013-sokuho20131018.pdf, (accessed 2018-09-06).

Cite This Article

Plain Text BibTeX RIS

APA Style

Mari Jibu, Yoshiyuki Osabe. (2018). Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding. American Journal of Information Science and Technology, 2(3), 64-73. https://doi.org/10.11648/j.ajist.20180203.11

Copy | Download

ACS Style

Mari Jibu; Yoshiyuki Osabe. Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding. Am. J. Inf. Sci. Technol. 2018, 2(3), 64-73. doi: 10.11648/j.ajist.20180203.11

Copy | Download

AMA Style

Mari Jibu, Yoshiyuki Osabe. Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding. Am J Inf Sci Technol. 2018;2(3):64-73. doi: 10.11648/j.ajist.20180203.11

Copy | Download

@article{10.11648/j.ajist.20180203.11,
  author = {Mari Jibu and Yoshiyuki Osabe},
  title = {Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding},
  journal = {American Journal of Information Science and Technology},
  volume = {2},
  number = {3},
  pages = {64-73},
  doi = {10.11648/j.ajist.20180203.11},
  url = {https://doi.org/10.11648/j.ajist.20180203.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajist.20180203.11},
  abstract = {For the sake of providing evidences that contribute to policy making or strategy planning in AMED (a Japanese version of the NIH) and pharmaceutical companies, this study tried to analyze a current state of the pharmaceutical industry based on new indicators and forecast the future thorough a series of papers. In this article, this study tried to give an overview of the funding trends for the drug development o this study analyzed 18,845 contracts between licensors and partners whose headquarters are located in the U.S. As a result, Major companies, SMEs are dealing not only with other SMEs but also dealing actively with government agencies and foundations in U.S. Government involvement is one of the most important aspects, because it provides innovation system structure to link each entity. The foundation also plays the important role as a funding partner in U.S. Focusing the role of SMEs in U.S., there are some transactions that SMEs buy the candidates of major companies on the discovery phase. On the other hands, investment from venture capital firms in Japan is one tenth of that in US. In AMED, introductory service of venture capital, commercialization, and government procurement will become useful systems.},
 year = {2018}
}

Copy | Download

TY  - JOUR
T1  - Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding
AU  - Mari Jibu
AU  - Yoshiyuki Osabe
Y1  - 2018/10/27
PY  - 2018
N1  - https://doi.org/10.11648/j.ajist.20180203.11
DO  - 10.11648/j.ajist.20180203.11
T2  - American Journal of Information Science and Technology
JF  - American Journal of Information Science and Technology
JO  - American Journal of Information Science and Technology
SP  - 64
EP  - 73
PB  - Science Publishing Group
SN  - 2640-0588
UR  - https://doi.org/10.11648/j.ajist.20180203.11
AB  - For the sake of providing evidences that contribute to policy making or strategy planning in AMED (a Japanese version of the NIH) and pharmaceutical companies, this study tried to analyze a current state of the pharmaceutical industry based on new indicators and forecast the future thorough a series of papers. In this article, this study tried to give an overview of the funding trends for the drug development o this study analyzed 18,845 contracts between licensors and partners whose headquarters are located in the U.S. As a result, Major companies, SMEs are dealing not only with other SMEs but also dealing actively with government agencies and foundations in U.S. Government involvement is one of the most important aspects, because it provides innovation system structure to link each entity. The foundation also plays the important role as a funding partner in U.S. Focusing the role of SMEs in U.S., there are some transactions that SMEs buy the candidates of major companies on the discovery phase. On the other hands, investment from venture capital firms in Japan is one tenth of that in US. In AMED, introductory service of venture capital, commercialization, and government procurement will become useful systems.
VL  - 2
IS  - 3
ER  -

Copy | Download

Author Information

Mari Jibu

Policy-Oriented Research Group, National Institute of Science and Technology Policy (NISTEP), Tokyo, Japan
Yoshiyuki Osabe

Patent Information Policy Planning Office, Japan Patent Office (JPO), Tokyo, Japan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Mari Jibu, Yoshiyuki Osabe. (2018). Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding. American Journal of Information Science and Technology, 2(3), 64-73. https://doi.org/10.11648/j.ajist.20180203.11

Copy | Download

ACS Style

Mari Jibu; Yoshiyuki Osabe. Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding. Am. J. Inf. Sci. Technol. 2018, 2(3), 64-73. doi: 10.11648/j.ajist.20180203.11

Copy | Download

AMA Style

Mari Jibu, Yoshiyuki Osabe. Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding. Am J Inf Sci Technol. 2018;2(3):64-73. doi: 10.11648/j.ajist.20180203.11

Copy | Download

@article{10.11648/j.ajist.20180203.11,
  author = {Mari Jibu and Yoshiyuki Osabe},
  title = {Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding},
  journal = {American Journal of Information Science and Technology},
  volume = {2},
  number = {3},
  pages = {64-73},
  doi = {10.11648/j.ajist.20180203.11},
  url = {https://doi.org/10.11648/j.ajist.20180203.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajist.20180203.11},
  abstract = {For the sake of providing evidences that contribute to policy making or strategy planning in AMED (a Japanese version of the NIH) and pharmaceutical companies, this study tried to analyze a current state of the pharmaceutical industry based on new indicators and forecast the future thorough a series of papers. In this article, this study tried to give an overview of the funding trends for the drug development o this study analyzed 18,845 contracts between licensors and partners whose headquarters are located in the U.S. As a result, Major companies, SMEs are dealing not only with other SMEs but also dealing actively with government agencies and foundations in U.S. Government involvement is one of the most important aspects, because it provides innovation system structure to link each entity. The foundation also plays the important role as a funding partner in U.S. Focusing the role of SMEs in U.S., there are some transactions that SMEs buy the candidates of major companies on the discovery phase. On the other hands, investment from venture capital firms in Japan is one tenth of that in US. In AMED, introductory service of venture capital, commercialization, and government procurement will become useful systems.},
 year = {2018}
}

Copy | Download

TY  - JOUR
T1  - Development of New Indicators for the Launch of Japan Agency for Medical Research and Development (AMED)-Trend Analysis for US NIH Funding
AU  - Mari Jibu
AU  - Yoshiyuki Osabe
Y1  - 2018/10/27
PY  - 2018
N1  - https://doi.org/10.11648/j.ajist.20180203.11
DO  - 10.11648/j.ajist.20180203.11
T2  - American Journal of Information Science and Technology
JF  - American Journal of Information Science and Technology
JO  - American Journal of Information Science and Technology
SP  - 64
EP  - 73
PB  - Science Publishing Group
SN  - 2640-0588
UR  - https://doi.org/10.11648/j.ajist.20180203.11
AB  - For the sake of providing evidences that contribute to policy making or strategy planning in AMED (a Japanese version of the NIH) and pharmaceutical companies, this study tried to analyze a current state of the pharmaceutical industry based on new indicators and forecast the future thorough a series of papers. In this article, this study tried to give an overview of the funding trends for the drug development o this study analyzed 18,845 contracts between licensors and partners whose headquarters are located in the U.S. As a result, Major companies, SMEs are dealing not only with other SMEs but also dealing actively with government agencies and foundations in U.S. Government involvement is one of the most important aspects, because it provides innovation system structure to link each entity. The foundation also plays the important role as a funding partner in U.S. Focusing the role of SMEs in U.S., there are some transactions that SMEs buy the candidates of major companies on the discovery phase. On the other hands, investment from venture capital firms in Japan is one tenth of that in US. In AMED, introductory service of venture capital, commercialization, and government procurement will become useful systems.
VL  - 2
IS  - 3
ER  -

Copy | Download